Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa.

about

Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa.

Item

http://www.wikidata.org/entity/Q41371210

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Switch of Intravitreal Therapy ...... hasone Implant and Vice Versa.

@en

type

Item

label

Switch of Intravitreal Therapy ...... hasone Implant and Vice Versa.

@en

prefLabel

Switch of Intravitreal Therapy ...... hasone Implant and Vice Versa.

@en

P1476

Switch of Intravitreal Therapy ...... thasone Implant and Vice Versa

@en

P2093

Anima Desiree Bühler

http://www.w3.org/2001/XMLSchema#string

Daniel Böhringer

http://www.w3.org/2001/XMLSchema#string

Sonja Ute Heinzelmann

http://www.w3.org/2001/XMLSchema#string

Thomas Ness

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus.

[Retinal vein occlusion: Therapy of retinal vein occlusion].

P304

5831682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/5831682

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Amelie Pielen

Bernd Junker

P577

2017-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28828184

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5554567

http://www.w3.org/2001/XMLSchema#string